Skip to content
Peptide research

Bronchogen

Category
Bioregulators
Administration routes
InjectableOral
Regulatory status
Not FDA-approved

Bronchogen is a short synthetic peptide marketed to repair bronchial cells and support airway gene regulation and mucus balance. Evidence is thin: benefits are low-confidence, based mainly on animal and mechanism-level work by one Russian group with no independent replication or human trials. The key gap is safety, with no established human safety profile or bioavailability data. It is not FDA-approved and sold only as an unregulated research compound.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Bronchogen is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Leu) developed through the Khavinson bioregulatory peptide program in Russia. It is designed to specifically target respiratory and lung tissue, where it modulates gene expression to support bronchial cell health and differentiation. It belongs to the Cytogens family of short peptide bioregulators.

How it works in the body

A short bioregulator peptide (Ala-Glu-Asp-Leu) that targets bronchial epithelial cells. It interacts with specific DNA sequences in these cells to normalize gene expression related to mucus production, ciliary function, and respiratory epithelial repair.

Research overview

Bronchogen works through an unusual mechanism for a peptide: rather than binding to cell surface receptors, it enters cells and interacts directly with DNA, activating genes critical for lung development and airway protection. In lab studies, it stimulates the maturation of bronchial lining cells, boosts local immune defenses (secretory IgA), and enhances surfactant production — the substance that keeps lung airways open. In animal models of chronic obstructive pulmonary disease (COPD), it reversed several hallmarks of the disease including excess mucus-producing cells, tissue damage, and inflammation while restoring healthy ciliated cells. It shows preferential activity in aged cell cultures, suggesting it may be most effective in older or damaged tissue. However, virtually all published research comes from a single research group (the Khavinson group in St. Petersburg), and no independent replication or controlled human clinical trials have been conducted in Western institutions.

Who researches Bronchogen?

Commonly researched by

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

  • People researching respiratory health

    Studied for effects on lung function, bronchial health, or respiratory tissue.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(9)

Rated by level of concern

  • No human clinical trials — safety and efficacy in humans unestablished

    High

    ClinicalTrials.gov and PubMed searches returned no human trials

  • Almost all research from single Russian research group (Khavinson) — no independent Western replication

    Moderate

    PMID 25015171; PMID 26468022

  • Theoretical concern: gene expression modulation (NKX2-1, FOXA1/2) could affect pre-existing lung malignancies

    Theoretical

    PMID 22383183 (shows opposite/context-dependent roles, not unidirectional oncogenic); PMID 25015171

  • Potential immune enhancement via sIgA upregulation may be contraindicated in autoimmune lung conditions

    Theoretical

    PMID 26468022

  • Long-term effects of chronic DNA-binding peptide administration unknown

    Theoretical

    PMID 25015171; PMID 26468022

  • Oral bioavailability not rigorously characterized in peer-reviewed studies

    Moderate

    No PK study identified; parenteral dosing per secondary sources (route not confirmed in PMID 26468022 abstract)

  • Quality varies significantly among unregulated products sold online — no pharmaceutical-grade manufacturing standards

    Moderate

    No FDA approval or USP monograph exists for this tetrapeptide

  • Pregnancy and lactation safety data absent

    Moderate

    No reproductive toxicology study identified

  • Interactions with bronchodilators, corticosteroids, and immunosuppressants unstudied

    Moderate

    No published co-administration or interaction study

Interaction summary(7)

Rated by direction with this peptide

  • Mucolytics / mucus-reducing therapy (N-acetylcysteine, carbocisteine, erdosteine)

    CautionTheoretical

    The peptide is reported to upregulate mucin genes (MUC4, MUC5AC) in bronchial epithelium — a full-text finding from a single in vitro study — which would in principle work against mucolytic therapy in hypersecretory phenotypes. The rodent data point the other way (reduced goblet cell hyperplasia), so the net direction is genuinely unknown and no co-administration has been tested.

    PMID 25015171 (in vitro, full text); PMID 26468022

  • Active lung cancer therapy (EGFR/ALK inhibitors, chemotherapy) or known lung adenocarcinoma

    CautionTheoretical

    The cited paper actually describes NKX2-1 and FOXA1 as having opposite, histology-dependent roles in lung cancer, so 'these factors drive adenocarcinoma growth' is not a supportable claim. The caution instead rests on the peptide being an unstudied modulator of epithelial proliferation markers (Ki67) and the anti-apoptotic factor Mcl-1, with zero tumor-model or carcinogenicity data in either direction. Avoiding an untested proliferative-signalling agent during active oncologic treatment is prudence, not a demonstrated interaction.

    PMID 22383183 (context-dependent roles); PMID 25015171

  • Immunosuppressants and biologics for autoimmune or interstitial lung disease (corticosteroids at immunosuppressive dose, rituximab, mycophenolate)

    CautionTheoretical

    Reported enhancement of mucosal sIgA in rats and modulation of the airway immune compartment could theoretically counteract deliberate immunosuppression. Single rodent finding; no co-administration study in any species.

    PMID 26468022

  • Inhaled corticosteroids (budesonide, fluticasone)

    NeutralTheoretical

    No pharmacokinetic or pharmacodynamic overlap has been demonstrated — both act on airway epithelium but by unrelated pathways, and no interaction study exists in any species.

    No published interaction study

  • Bronchodilators (beta-2 agonists, LAMA/SAMA anticholinergics)

    NeutralTheoretical

    No reported activity at adrenergic or muscarinic receptors and no smooth-muscle effect has been measured, so no mechanistic basis for interference or synergy is established.

    No published interaction study

  • Antifibrotics (pirfenidone, nintedanib)

    NeutralTheoretical

    The only basis for expecting additive benefit is a bleomycin rat fibrosis report that is not indexed in PubMed, so it cannot support a directional claim. With no reliable anti-fibrotic data and no combination study in any species, neither synergy nor interference is established — and antifibrotics have narrow tolerability margins, so adding an uncharacterized agent is untested territory.

    No primary fibrosis data; no combination study

  • CYP450-metabolized drugs generally (theophylline, macrolides, azoles)

    NeutralTheoretical

    As a tetrapeptide expected to be cleared by ubiquitous peptidases rather than hepatic oxidation, there is no plausible CYP inhibition or induction liability — but this is inference only, as no CYP assay has been published.

    Mechanistic inference; no CYP assay published

Known risks(9)

  • No human clinical trials — safety and efficacy in humans unestablished

  • Almost all research from single Russian research group (Khavinson) — no independent Western replication

  • Theoretical concern: gene expression modulation (NKX2-1, FOXA1/2) could affect pre-existing lung malignancies

  • Potential immune enhancement via sIgA upregulation may be contraindicated in autoimmune lung conditions

  • Long-term effects of chronic DNA-binding peptide administration unknown

  • Oral bioavailability not rigorously characterized in peer-reviewed studies

  • Quality varies significantly among unregulated products sold online — no pharmaceutical-grade manufacturing standards

  • Pregnancy and lactation safety data absent

  • Interactions with bronchodilators, corticosteroids, and immunosuppressants unstudied

Drug interactions(6)

  • Corticosteroids (inhaled/systemic)

    Bronchogen modulates inflammatory cytokines and sIgA; concurrent corticosteroid use may produce competing immunomodulatory effects. No interaction studies conducted.

  • Bronchodilators (beta-2 agonists, anticholinergics)

    Both target bronchial tissue through different mechanisms. No interaction data available. Theoretical synergy but unstudied.

  • Immunosuppressants

    Bronchogen enhances local immune defense (sIgA); immunosuppressants work in opposition. Concurrent use may reduce efficacy of either agent.

  • Chonluten (EDG tripeptide)

    Related Khavinson respiratory peptide. Both target bronchopulmonary tissue through complementary mechanisms. Used together in some Russian bioregulator protocols.

  • Other Khavinson peptides (Epithalon, Thymalin, Vilon)

    Khavinson protocols often combine organ-specific bioregulators. No formal interaction studies but decades of reported combined use in Russian clinical practice.

  • Mucolytics (NAC, guaifenesin)

    Both affect mucus production and airway secretions. No interaction data available.

Research & benefits

Evidence base

Evidence Level
Preclinical
Total Studies
8
Human Studies
0

All evidence derives from in vitro cell culture studies (human bronchial epithelial cell lines) and in vivo rat models (NO2-induced COPD). Research spans approximately 2006-2022 and originates almost entirely from Russian institutions affiliated with V.Kh. Khavinson. No independent replication by non-Russian research groups. No randomized controlled human trials. Evidence is promising but limited and lacks independent verification.

Researched for(8)

Rated by confidence in the evidence

  • Bronchial epithelial restoration

    Low

    Reversed epithelial damage in a rat COPD model and in vitro, no human trials yet.

    PMID 26468022; PMID 25015171

  • Anti-inflammatory (respiratory)

    Low

    Reduced inflammatory markers and cell infiltration in a single rat COPD study.

    PMID 26468022

  • Local immune defense enhancement

    Speculative

    Increased secretory IgA in one rat study, without any infection-clearance testing.

    PMID 26468022

  • Surfactant production support

    Speculative

    Cell studies measured a surfactant-related gene; a separate rat COPD study measured increased surfactant protein B in bronchoalveolar lavage fluid (PMID 30199201).

    PMID 25015171

  • DNA stabilization

    Speculative

    A laboratory experiment directly measured DNA stabilization, reporting a 3.1°C increase in melting temperature; clinical significance remains unknown (PMID 21240358).

    PMID 25015171

  • Gene regulation for lung health

    Low

    Modulated several lung-differentiation genes in cultured human cells, clinical relevance remains unproven.

    PMID 25015171

  • Age-related tissue repair

    Speculative

    Based on stronger effects in older cell cultures, not tested in aged animals or humans.

    PMID 25015171

  • Anti-fibrotic potential

    Low

    Lessened, not prevented, lung fibrosis in a rat bleomycin model per the inventor's own patent filing.

    US Patent 7,625,870 (Khavinson et al., filed 2004), Example 3 rat bleomycin fibrosis study; a patent disclosure, not a peer-reviewed or PubMed-indexed publication.

Benefits(8)

  • Bronchial epithelial restoration

  • Anti-inflammatory (respiratory)

  • Local immune defense enhancement

  • Surfactant production support

  • DNA stabilization

  • Gene regulation for lung health

  • Age-related tissue repair

  • Anti-fibrotic potential

Key studies(6)

  1. Khavinson VKh, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, Ashapkin VV, Polyakova VO, Basharina VS, Bernadotte A

    Lung

    2014

    ADEL modulated Ki67, Mcl-1, p53, CD79, NOS-3 proteins and regulated NKX2-1, SCGB1A1, SCGB3A2, FOXA1, FOXA2 gene expression in bronchial epithelial cells. Binds DNA major groove at guanine residues.

  2. Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, Surkova EA, Platonova IS, Titova ON

    Bull Exp Biol Med

    2015

    1-month Bronchogen treatment in NO2-induced COPD rats eliminated goblet cell hyperplasia, squamous metaplasia, lymphocytic infiltration, emphysema. Restored ciliated cells and enhanced sIgA production.

  3. Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, Khachidze DG, Lomidze EM, Jokhadze TA, Lezhava TA

    Bull Exp Biol Med

    2011

    Bronchogen increased DNA melting temperature by 3.1 degrees C via strong, non-specific binding to nitrogenous bases. DNA-stabilizing effect observed at molar ratios 0.01-0.055.

  4. Titova ON, Kuzubova NA, Lebedeva ES, Preobrazhenskaya TN, Surkova EA, Dvorakovskaya IV

    Ross Fiziol Zh Im I M Sechenova

    2017

    Bronchogen reduced neutrophilic inflammation, normalized cytokine profiles, restored bronchial epithelial structure, and increased sIgA and surfactant protein B in COPD rat model.

  5. Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM

    Bull Exp Biol Med

    2012

    Bronchogen (AEDL) stimulated CXCL12 and Hoxa3 differentiation markers in bronchial epithelial cultures, with stronger effects in aged cultures. WEGC1 findings concerned prostatic fibroblasts treated with vesugen.

  6. Zakutskii AN, Chalisova NI, Ryzhak GA, Aniskina AI, Filippov SV, Zeziulin PN

    Adv Gerontol

    2006

    Bronchogen at 0.05 ng/ml showed organ-specific stimulating effects in lung tissue cultures from both young and old rats, supporting reparative processes during aging.

Regulation & availability

Why researchers look at it

In animal models of COPD, Bronchogen reversed excess mucus-producing cells, tissue damage, and inflammation while restoring healthy ciliated cells and boosting local immune defenses — with preferential activity in aged tissue. All published research comes from a single group (the Khavinson lab in St. Petersburg), with no independent replication or controlled human trials in Western institutions. If independent researchers validate these findings, it could become a notable entry in respiratory peptide therapeutics.

Estimated cost
$30-80/mo oral capsules
FDA status
Bronchogen is not FDA-approved and is not eligible for compounding in the US. IND and NDA submission status is unconfirmed. FDA generally does not disclose whether an IND exists unless it has previously been publicly disclosed or acknowledged. In Russia, it is available as a dietary supplement (not a registered pharmaceutical).
WADA status
Not individually named in the 2026 list. S0 prohibits pharmacological substances without governmental approval for human therapeutic use. Confirm whether any qualifying approval exists before athletic use.
Prescribability
Research only (March 2026). Not FDA-approved. Available as dietary supplement in Russia and some Eastern European countries.
Availability
Available as an oral capsule supplement in Russia and Eastern European countries through the Peptide Bioregulator product line. Not available through standard US pharmacies or compounding pharmacies. Unregulated products are also sold online and vary in purity.

International status

  • EU

    Not approved

  • US

    Not approved

  • Russia

    Used clinically (Khavinson bioregulator protocol)

  • Worldwide

    Limited to Russian clinical use

Regulatory timeline(8)

  1. 1973-2000s
    Khavinson peptide program developmentV.Kh. Khavinson developed peptide bioregulators from animal tissue extracts at St. Petersburg Institute of Bioregulation and Gerontology. Bronchogen synthesized as short-peptide analog of bronchial mucosa extract.
  2. 2006
    First published organotypic tissue studyZakutskii et al. demonstrated tissue-specific effects of Bronchogen in lung cultures from young and old rats (Adv Gerontol).
  3. 2011
    DNA thermostability study publishedMonaselidze et al. showed Bronchogen stabilizes DNA, increasing melting temperature by 3.1 degrees C (Bull Exp Biol Med).
  4. 2012
    Age-related differentiation studyKhavinson et al. demonstrated tissue-specific stimulation of differentiation factors in aged bronchial epithelial cells (Bull Exp Biol Med).
  5. 2014
    Comprehensive gene regulation studyKhavinson et al. published key study in Lung journal showing ADEL regulation of NKX2-1, SCGB1A1, SCGB3A2, FOXA1, FOXA2 genes and DNA binding mechanism.
  6. 2015
    COPD rat model studyKuzubova et al. showed Bronchogen reverses COPD pathology in NO2-exposed rats (Bull Exp Biol Med).
  7. 2017
    Anti-inflammatory COPD studyTitova et al. confirmed anti-inflammatory and regenerative effects in COPD model with cytokine normalization and surfactant protein B restoration.
  8. 2026-03
    Current statusRemains research-only compound. No FDA approval pathway active. No human clinical trials registered on ClinicalTrials.gov.

Sources & FAQs

Research sources(7)

Frequently asked questions(6)

What is Bronchogen?

Bronchogen is a synthetic tetrapeptide (Ala-Glu-Asp-Leu, or AEDL) bioregulator developed through the Khavinson peptide research program in Russia. It is designed to target bronchial and pulmonary tissue, modulating gene expression related to respiratory health.

Is Bronchogen safe?

Animal studies show a favorable safety profile with no significant adverse effects at research doses. However, no human clinical trials have been conducted, so safety in humans has not been formally established. The absence of observed toxicity in limited animal studies does not guarantee human safety.

How is Bronchogen administered?

Available as oral capsules, with courses repeated in Russian supplement practice. Oral formulations may use enteric coating for bioavailability.

Does Bronchogen have human clinical trial data?

No. All published evidence comes from in vitro cell culture studies and in vivo rat models. No randomized controlled human trials have been published in peer-reviewed journals.

How does Bronchogen differ from Chonluten?

Both are Khavinson respiratory peptides. Bronchogen (AEDL, tetrapeptide) targets bronchial epithelial cell differentiation and gene regulation. Chonluten (EDG, tripeptide) is derived from bronchial/lung tissue and has demonstrated TNF inhibition in monocyte studies.

Is there independent verification of Bronchogen research?

Almost all research originates from Russian institutions affiliated with V.Kh. Khavinson. One notable exception is a 2022 study in Int J Mol Sci by Avolio et al. (Italian/Russian collaboration) that studied related Khavinson peptides. Independent Western replication of Bronchogen-specific findings remains absent.